{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:29:43Z","timestamp":1771327783420,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T00:00:00Z","timestamp":1271980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>\n                    (\n                    <jats:italic>Headache<\/jats:italic>\n                    2010;50:795\u2010807)\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives.\u2014<\/jats:bold>\n                    This study evaluated the long\u2010term safety of oral almotriptan 12.5\u2003mg for the treatment of multiple migraine episodes in adolescents over a 12\u2010month period. Efficacy outcomes were assessed as a secondary objective.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    Adolescent migraineurs aged 12\u201017 years were enrolled in this 12\u2010month, open\u2010label study (Study ID CR002827). Patients were instructed to record their assessments on paper headache records whenever they experienced a migraine headache that they treated with study medication. Safety was assessed descriptively and assessments included adverse event (AE) recording, change in laboratory values, vital signs, and electrocardiogram parameters. Efficacy outcomes were assessed descriptively and outcomes included rates for 2\u2010 and 24\u2010hour pain relief and sustained pain relief, 2\u2010 and 24\u2010hour pain\u2010free and sustained pain\u2010free, and presence of migraine\u2010associated symptoms of photophobia, phonophobia, nausea and vomiting.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    Overall, 67.1% of patients reported \u22651 AE over the course of the trial, 7.6% had an AE judged by the study investigator to be related to treatment with almotriptan, 2.4% discontinued because of an AE, and 1.9% reported serious AEs. The most commonly reported treatment\u2010related AEs (occurring in \u22651% of patients) were nausea (1.4%) and somnolence (1.4%). Pain relief responses for treated migraines of moderate or severe intensity at baseline were 61.7% and 68.6%, at 2 and 24 hours, respectively; the sustained pain relief rate was 55.5%. Pain\u2010free responses were reported for 40.5% of all treated migraines at 2 hours and 65.9% of treated migraines at 24 hours; the sustained pain\u2010free rate was 38.4%. The proportion of migraines that achieved the pain relief, sustained pain relief, pain\u2010free and sustained pain\u2010free endpoints were similar in the 12\u2010 to 14\u2010year and 15\u2010 to 17\u2010year age groups. Treating with almotriptan 12.5\u2003mg when headache pain was mild was associated with higher rates of pain relief and pain\u2010free at 2 and 24 hours, and sustained pain relief and sustained pain\u2010free, compared with treatment initiated when pain was severe.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Almotriptan 12.5\u2003mg was well tolerated in this adolescent population over a 12\u2010month period. No unexpected safety or tolerability concerns were revealed over the course of this study. The results are consistent with almotriptan 12.5\u2003mg being effective for the acute treatment of pain and symptoms associated with migraine in both younger and older adolescents.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2010.01655.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T12:36:36Z","timestamp":1272026196000},"page":"795-807","source":"Crossref","is-referenced-by-count":11,"title":["Long\u2010Term, Open\u2010Label Safety Study of Oral Almotriptan 12.5\u2003mg for the Acute Treatment of Migraine in Adolescents"],"prefix":"10.1111","volume":"50","author":[{"given":"Frank","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elza","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Pakalnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,23]]},"reference":[{"issue":"9","key":"e_1_2_7_2_2","first-page":"63","article-title":"Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine","volume":"9","author":"Perrin VL","year":"1989","journal-title":"Cephalalgia"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1999.3907494.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.5.989"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00339.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0085"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04171.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02013.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00313.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00755.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-006-0288-0"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01138.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80083-1"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2000.00144.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00895.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04074.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00981.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00602.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00466.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.00981.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00756.x"},{"key":"e_1_2_7_22_2","first-page":"1393","article-title":"\u2018ACT when mild\u2019: Early vs. non\u2010early almotriptan intervention in migraine","volume":"26","author":"Goadsby PJ","year":"2006","journal-title":"Cephalalgia"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01546.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00735.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04125.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02010.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00802.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.00260.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085039"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03208.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00686.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000231138.18629.d5"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2010.01655.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2010.01655.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:21:32Z","timestamp":1762075292000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2010.01655.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,23]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1526-4610.2010.01655.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01655.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,23]]}}}